Our Research Program
At Nabriva, our research program is based on our large and diverse proprietary compound library. We believe that our expertise in the areas of medicinal chemistry, pharmacology, and toxicology have enabled targeted discovery of novel pleuromutilins through modification of side chains and core positions in the mutilin moiety. These modifications have resulted in alterations in microbial activity, ADME, and toxicity of the semi-synthetic molecules.
We are actively pursuing an in-house discovery program to sustain our pipeline with future product candidates. The aim of this program is (1) the development of novel pleuromutilins with enhanced affinity for the bacterial ribosome site where they bind and inhibit bacterial growth, directed at increasing the antimicrobial potency, and (2) broadening the spectrum of activity to include rare strains with known mechanisms of resistance (e.g., cfr or Vga mutants). We believe next-generation pleuromutilins have the potential to exhibit improved antibacterial activity and a pharmacokinetic profile that may make them well suited for the treatment of respiratory tract infections, acute/complicated bacterial skin infections, sexually transmitted infections, and biothreat organisms.